Exhibit 1

JOINT FILING AGREEMENT

        The undersigned hereby agree that the Amendment No. 2 to the Statement on Schedule 13D, dated April 28, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 2^nd day of May 2023.

ORBIMED ADVISORS LLC
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Member
ORBIMED ASIA GP IV, L.P.
By:	ORBIMED ADVISORS IV LIMITED, its general partner
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Director of OrbiMed Advisors IV Limited
ORBIMED ADVISORS IV LIMITED
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Director
ORBIMED CAPITAL GP VII LLC
By:	ORBIMED ADVISORS LLC, its managing member
By:	s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Member of OrbiMed Advisors LLC
ORBIMED GENESIS GP LLC
By:	ORBIMED ADVISORS LLC, it’s managing member
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Member of OrbiMed Advisors LLC

ORBIMED CAPITAL LLC
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Member
ORBIMED CAPITAL GP VIII LLC
By:	ORBIMED ADVISORS LLC, its managing member
By:	s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Member of OrbiMed Advisors LLC